预约演示
FDA's early review finds no evidence linking Novo, Lilly weight-loss drugs to suicidal thoughts
2024-01-12
After reviewing data from clinical trials and observational studies, the FDA's preliminary review found no link to GLP-1 medicines and suicidal thoughts.
A preliminary evaluation by the FDA found no evidence that use of popularFDAabetes and weight-loss drugs from Novo Nordisk and Eli Lilly can cause suicidal thoughts, the U.S. regulator said.
Over the last several months, thFDAgency has been looking into reports of diabetes thoughts or actions from usNovo NordiskLP-1 Eli Lillys gathered through its FDA Adverse Event Reporting System (FAERS), it said.
“Because the information provided was often limited and because these events can be influenced by other potential factorsGLP-1determined that the information in these reports did not demonstrate a clear relationship with the use of (GLP-1s),” the FDA wrote. The agency said its reviews of clinical trials and observational studies found no association between the treatments and suicidal thoughts.
Ten days ago, the FDA drew attention when it included the trendy therapies on a list of medicines it said it was monitoring for side effects. In the case of Novo’s semaglutide and Lilly’s tirzepatide, those side effects also includedGLP-1scia (haiFDAoss) and aspiration, a dangerous condition often associated with surgery in which people breathe food, liquid, vomit or saliva into their lungs.
In Thursday’s FDA FDAate, the agency did not address those other potential side effects.semaglutideLillytirzepatidealopeciahair loss
Also last weekFDAature Journal reported that a study of 1.8 million patients in the United States found that those who were using Novo’s drugs such as Ozempic and Wegovy were less likely to have suicidal thoughts compared to patients who were using other diabetes and obesity treatments.
As demand has skyrocketed for the blood sugar-moderating drugs produced by Novo and Lilly, they have come under increased scrutiny. In July of last yeaOzempicEuropWegovydicines Agency began investigating Ozempic and Wegovy after reports from Iceland detaidiabetesidal obesitys from two users and self-harm from another. That review is ongoing.
GLP-1 drugs already include label warnings about a rare intestinal blockageNovoditioLillyled ileus, which can be life-threatening.European Medicines AgencyOzempicWegovy
GLP-1 drugstember of last year, the FDA had received 201 reports of suicidal thoughts from usileusf semaglutide or tirzepatide. In Thursday’s update, the FDA said that it would continue to monitor suicidal ideation in clinical trials and review data from the Sentinel System, a large network that includes health insurance claims and patient records that can be used to investigate safety questions about FDA-approved products.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。